We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

108 hedge funds and large institutions have $938M invested in Portola Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more call options, than puts

Call options by funds: $531K | Put options by funds: $222K

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

2% less funds holding

Funds holding: 110108 (-2)

10% less capital invested

Capital invested by funds: $1.05B → $938M (-$110M)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
108
Holders Change
-2
Holders Change %
-1.82%
% of All Funds
3.13%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
14
Increased
39
Reduced
26
Closed
16
Calls
$531K
Puts
$222K
Net Calls
+$309K
Net Calls Change
-$144K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$126M -$3.25M -123,287 -2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$117M +$9.22M +349,970 +8%
Temasek Holdings
3
Temasek Holdings
Singapore
$107M
Franklin Resources
4
Franklin Resources
California
$45.4M +$4.19M +159,100 +10%
EAM
5
Eagle Asset Management
Florida
$43.7M +$2.92M +110,937 +7%
Vanguard Group
6
Vanguard Group
Pennsylvania
$42M +$8.46M +321,191 +24%
SAM
7
Sectoral Asset Management
Quebec, Canada
$35.7M +$1.24M +47,198 +3%
BFA
8
BlackRock Fund Advisors
California
$32.8M -$37K -1,403 -0.1%
JP Morgan Chase
9
JP Morgan Chase
New York
$31.1M -$2.34M -88,957 -7%
MAM
10
MPM Asset Management
Massachusetts
$30.9M
A
11
Abingworth
United Kingdom
$23.5M -$8.17M -310,230 -25%
O
12
OrbiMed
New York
$21.5M -$13.5M -510,900 -38%
OTPPB
13
Ontario Teachers' Pension Plan Board
Ontario, Canada
$17.5M
Jennison Associates
14
Jennison Associates
New York
$16.2M +$25.3K +959 +0.1%
FAM
15
Fred Alger Management
New York
$15.7M -$64.2K -2,438 -0.4%
DM
16
Deerfield Management
New York
$14.1M -$721K -27,371 -5%
State Street
17
State Street
Massachusetts
$14.1M +$773K +29,334 +6%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$13.1M -$1.31M -49,926 -9%
PC
19
Polar Capital
United Kingdom
$12.6M +$3.57M +135,454 +37%
Millennium Management
20
Millennium Management
New York
$12.1M +$8.25M +313,198 +191%
Northern Trust
21
Northern Trust
Illinois
$11.1M +$7.25M +275,348 +167%
BIT
22
BlackRock Institutional Trust
California
$10.1M -$16.6K -631 -0.2%
EAM
23
Eventide Asset Management
Massachusetts
$9.41M
AllianceBernstein
24
AllianceBernstein
Tennessee
$8.26M -$709K -26,900 -8%
EA
25
Emerald Advisers
Pennsylvania
$8.02M +$728K +27,647 +10%

PTLA Hedge Fund Activity: Q3 2014 in Review

108 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2014, worth a combined $938M — down 10% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PTLA and 14 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 39 added.

The largest buyer was Fidelity Investments, adding an estimated $9.22M. The largest seller was OrbiMed, cutting an estimated $13.5M.

  • 108 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2014, down from 110 in Q2 2014.
  • Funds reported $938M of Portola Pharmaceuticals, Inc. stock for Q3 2014, down 10% quarter-over-quarter.
  • 14 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2014 and 16 closed out, a net change of -2 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2014 was Fidelity Investments, an estimated $9.22M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2014 was OrbiMed, an estimated $13.5M sold.

Based on aggregated 13F filings for Q3 2014.